NVCR
HoldHot AirNovoCure Limited · Healthcare · Switzerland · $2.1B · Avg Vol: $20M/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT NOVOCURE LIMITED
Read
NovoCure Limited is a global oncology company focused on developing and commercializing its proprietary Tumor Treating Fields (TTFields) technology for various solid tumor cancers. TTFields are electric fields that disrupt cancer cell division, representing a novel, non-invasive therapeutic modality. The company's competitive advantage lies in its unique technology, which has regulatory approvals for glioblastoma and mesothelioma, positioning it as an innovator in cancer treatment with a growing intellectual property portfolio.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.8M | 509.3M | 605.2M | 655.4M | 6.8% | 699.2M | 725.9M | 804.8M | 10.8% |
| EPS | -0.88 | -1.95 | -1.56 | -1.22 | — | -1.30 | -1.25 | -0.82 | — |
| Shares | 105.0M | 107.1M | 108.5M | 112.5M | +7.1% | 116.4M | — | — | — |
| Debt | 584.3M | 604.6M | 683.3M | 248.4M | -24.8% | 233.4M | — | — | — |
| Equity | 441.2M | 362.5M | 360.2M | 340.5M | -8.3% | — | — | — | — |
| Op CF | 30.8M | -73.3M | -26.4M | -49.0M | — | — | — | — | — |
| Inv CF | -140.0M | 184.1M | -140.2M | 437.3M | — | — | — | — | — |
| Fin CF | 15.5M | 15.8M | 90.3M | -451.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVCR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NVCR | NovoCure Limited(you) | $2.1B | 40 | Hold |
| MED.SW | Medartis Holding AG | $1.4B | 39 | Hold |
| MOVE.SW | Medacta Group SA | $3.1B | 39 | Hold |
| KURN.SW | Kuros Biosciences AG | $1.0B | 33 | Sell |
| METN.SW | Metall Zug AG | $483M | 49 | Hold |
| SOON.SW | Sonova Holding AG | $17.2B | 77 | Buy |
| PPGN.SW | PolyPeptide Group AG | $1.8B | 51 | Hold |
| AEVS.SW | Aevis Victoria SA | $1.4B | 34 | Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 22 | Sell |
| SFZN.SW | Siegfried Holding AG | $4.0B | 50 | Hold |
Peer medians: ROE 11.1% · P/E 29.9x · Gross margin 58.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.